Jasper Therapeutics (Nasdaq: JSPR) outlines $30M CVR tied to briquilimab
Rhea-AI Filing Summary
Jasper Therapeutics, Inc. describes contingent value rights granted in connection with its acquisition of Kira Pharmaceuticals. Each holder of voting common stock of Jasper of record immediately before the merger’s Effective Time is entitled to one contractual contingent value right (CVR) per share.
Each CVR gives the holder a pro rata portion of a $30.0 million Milestone Payment if the U.S. Food and Drug Administration issues a Priority Review Voucher for briquilimab on or before December 31, 2028. Payment timing depends on any Change of Control and a Monetization Event, with payment generally due within 90 days after monetization. The CVRs are generally non-transferable, not certificated, and not registered or listed. The record date for CVR eligibility was July 16, 2026, the closing date of the Kira acquisition.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Milestone Payment: $30.0 million
Expiration Date: December 31, 2028
Record date for CVRs: July 16, 2026
+3 more
6 metrics
Milestone Payment
$30.0 million
Aggregate amount payable to CVR holders if the Milestone is achieved
Expiration Date
December 31, 2028
Latest date by which a Priority Review Voucher must be issued for briquilimab
Record date for CVRs
July 16, 2026
Date of the closing of the Kira acquisition and CVR eligibility record date
Payment timing after Monetization
90 days
Milestone Payment due 90 days following the Monetization Event when applicable
Warrant exercise price
$115.00
Each ten warrants exercisable for one share of Voting Common Stock at this price
Common stock par value
$0.0001
Par value per share of Jasper’s Voting Common Stock
Key Terms
contingent value right, Priority Review Voucher, Change of Control, Monetization Event, +1 more
5 terms
contingent value right financial
"each holder ... is entitled to one (1) contractual contingent value right"
A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.
Priority Review Voucher regulatory
"if the United States Food and Drug Administration issues a Priority Review Voucher"
A priority review voucher is a transferable regulatory incentive that lets a company move a future drug or device application to the front of the review line, shortening the review period by several months. For investors it matters because the voucher can speed up market access for a high-value product or be sold to other companies for significant cash, acting like a tradable fast-pass that can accelerate revenue or create immediate financial upside.
Change of Control financial
"If the Milestone is achieved ... and the Company undergoes a Change of Control"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
Monetization Event financial
"ninety (90) days following the Monetization Event"
Expiration Date financial
"on or prior to December 31, 2028 (the “Expiration Date”)"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What contingent value right (CVR) did Jasper Therapeutics (JSPR) grant in the Kira acquisition?
Jasper Therapeutics granted one contingent value right (CVR) for each share of voting common stock held immediately before the merger’s Effective Time. Each CVR entitles its holder to a share of a potential $30.0 million Milestone Payment tied to a regulatory outcome for briquilimab.
When will Jasper Therapeutics (JSPR) pay the CVR Milestone Payment if the Milestone is achieved?
If the Milestone is achieved and Jasper undergoes a Change of Control, the Milestone Payment is due on the earlier of the Change of Control closing or 90 days after a Monetization Event. Without a prior Monetization Event, payment occurs 90 days after that Monetization Event.
What is the Expiration Date for the JSPR CVR Milestone linked to briquilimab?
The Milestone must be achieved by December 31, 2028, defined as the Expiration Date. If the Priority Review Voucher is issued by then, CVRs remain in effect until the $30.0 million Milestone Payment is fully paid, even if monetization occurs after the Expiration Date.
Who was eligible to receive the Jasper Therapeutics (JSPR) CVRs from the Kira transaction?
Eligibility was based on being a holder of Jasper voting common stock of record on July 16, 2026, the Kira acquisition closing date. Each such holder received one CVR per share, subject to the detailed terms of the CVR Agreement referenced in the merger documentation.
Are the Jasper Therapeutics (JSPR) CVRs transferable or traded on an exchange?
The CVRs are generally not transferable, except in limited circumstances set out in the CVR Agreement. They will not be certificated, will not be registered with the SEC, and will not be listed for trading on any securities exchange.